Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by SanFrancisco99on Jul 05, 2014 2:41pm
227 Views
Post# 22718506

RE:RE:Other Deals

RE:RE:Other DealsYes, Sir!  That's right, Sir!  

My thinking too.  Clearly we have heard a very, very clear message from management (share purchases), directors (share purchases), the CEO (big share purchase), the COB (multiple transactions), and Dart/Eastern (multiple transactions) that they all believe that RVX-208 is the real deal.  And very valuable.

If they are all so convinced, it is because the cumulative ("enormous") amount of data is very clear - even at this stage in the game.  That's why they are convinced.

Given this, pharma must know it too.  And that means multiple pharma.  They all know it now.

Which means that the real issue is likely one of priced/terms in a deal.  Nothing else....  IMHO.  Price and terms.

I think Don, Dart and team want a high price - either for a transaction now or one later on (lower "high" price today, higher "high" price tomorrow - but no fire sales.  Quite to the contrary.).   I personally think there's a high-stakes, multi-party negotiation going on right now.  This Citi/Eastern arrangement is just another poker move - and a very important one.  It tells the pharma:  WE DON'T NEED YOU.  YOU NEED US.

That high-stakes negotiation could get resolved any day.  Or it might get resolved after RE-MACE.  We just don't know.

But what we do know is this:  We clearly have something very, very valuable.  Worth a lot more than 90 cents.  There's too much evidence of that lately.

IMHO.  DYODD.  









Bullboard Posts